Strategic Initiative

Slingshot members are tracking this corporate initiative:

Sanofi (SNY) Reaches Global License Agreement to Develop ImmuNext's INX-021 in a Range of Autoimmune Diseases Including Lupus and Multiple Sclerosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SNY

100%
ImmuNext

100%
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 09, 2017
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Global License Agreement, Inx-021, Autoimmune Hemolytic Diseases, Lupus, Multiple Sclerosis